Nooglutyl

Last updated
Nooglutyl
Nooglutyl.svg
Names
IUPAC name
N-[(5-Hydroxy-3-pyridinyl)carbonyl]-L-glutamic acid
Systematic IUPAC name
(2S)-2-(5-Hydroxypyridine-3-carboxamido)pentanoic acid
Other names
Nooglutil
Identifiers
3D model (JSmol)
ChemSpider
PubChem CID
UNII
  • InChI=1S/C11H12N2O6/c14-7-3-6(4-12-5-7)10(17)13-8(11(18)19)1-2-9(15)16/h3-5,8,14H,1-2H2,(H,13,17)(H,15,16)(H,18,19)/t8-/m0/s1
    Key: XFZGYOJFPGPYCS-QMMMGPOBSA-N
  • InChI=1/C11H12N2O6/c14-7-3-6(4-12-5-7)10(17)13-8(11(18)19)1-2-9(15)16/h3-5,8,14H,1-2H2,(H,13,17)(H,15,16)(H,18,19)/t8-/m0/s1
    Key: XFZGYOJFPGPYCS-QMMMGPOBBD
  • O=C(c1cncc(O)c1)N[C@H](C(=O)O)CCC(=O)O
Properties
C11H12N2O6
Molar mass 268.225 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Nooglutyl is a nootropic agent that was studied at the Research Institute of Pharmacology, Russian Academy of Medical Sciences as a potential treatment for amnesia. [1]

In animal models, it has a variety of central nervous system effects. [2] [3] [4] [5]

Nooglutyl has some structural similarities to Picamilon (N-Nicotinoyl-GABA). Nooglutyl is N-5-HydroxyNicotinoyl-L-Glutamic acid.

Related Research Articles

An anxiolytic is a medication or other intervention that reduces anxiety. This effect is in contrast to anxiogenic agents which increase anxiety. Anxiolytic medications are used for the treatment of anxiety disorders and their related psychological and physical symptoms.

<span class="mw-page-title-main">20-Hydroxyecdysone</span> Chemical compound

20-Hydroxyecdysone is a naturally occurring ecdysteroid hormone which controls the ecdysis (moulting) and metamorphosis of arthropods. It is therefore one of the most common moulting hormones in insects, crabs, etc. It is also a phytoecdysteroid produced by various plants, including Cyanotis vaga, Ajuga turkestanica and Rhaponticum carthamoides where its purpose is presumably to disrupt the development and reproduction of insect pests. In arthropods, 20-hydroxyecdysone acts through the ecdysone receptor. Although mammals lack this receptor, 20-hydroxyecdysone affects mammalian biological systems. 20-Hydroxyecdysone is an ingredient of some supplements that aim to enhance physical performance. In humans, it is hypothesized to bind to the estrogen receptor beta (ERβ) protein-coding gene.

Histamine H<sub>3</sub> receptor Mammalian protein found in Homo sapiens

Histamine H3 receptors are expressed in the central nervous system and to a lesser extent the peripheral nervous system, where they act as autoreceptors in presynaptic histaminergic neurons and control histamine turnover by feedback inhibition of histamine synthesis and release. The H3 receptor has also been shown to presynaptically inhibit the release of a number of other neurotransmitters (i.e. it acts as an inhibitory heteroreceptor) including, but probably not limited to dopamine, GABA, acetylcholine, noradrenaline, histamine and serotonin.

<span class="mw-page-title-main">Phenylpiracetam</span> Chemical compound

Phenylpiracetam, is a phenylated analog of the drug piracetam. It was developed in 1983 as a medication for Soviet Cosmonauts to treat the prolonged stresses of working in space. Phenylpiracetam was created at the Russian Academy of Sciences Institute of Biomedical Problems in an effort led by psychopharmacologist Valentina Ivanovna Akhapkina. In Russia it is now available as a prescription drug. Research on animals has indicated that phenylpiracetam may have anti-amnesic, antidepressant, anticonvulsant, anxiolytic, and memory enhancement effects.

Human enhancement is the natural, artificial, or technological alteration of the human body in order to enhance physical or mental capabilities.

<span class="mw-page-title-main">Gidazepam</span> Benzodiazepine medication

Gidazepam, also known as hydazepam or hidazepam, is a drug which is an atypical benzodiazepine derivative, developed in the Soviet Union. It is a selectively anxiolytic benzodiazepine. It also has therapeutic value in the management of certain cardiovascular disorders.

<span class="mw-page-title-main">Corticotropin-like intermediate peptide</span> Chemical compound

Corticotropin-like intermediate [lobe] peptide (CLIP), also known as adrenocorticotropic hormone fragment 18-39, is a naturally occurring, endogenous neuropeptide with a docosapeptide structure and the amino acid sequence Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe. CLIP is generated as a proteolyic cleavage product of adrenocorticotropic hormone (ACTH), which in turn is a cleavage product of proopiomelanocortin (POMC). Its physiological role has been investigated in various tissues, specifically in the central nervous system.

<span class="mw-page-title-main">Mesocarb</span> Stimulant drug

Mesocarb is a drug that is currently being developed for Parkinson's disease.

<span class="mw-page-title-main">Latrepirdine</span> Antihistamine drug

Latrepirdine is an antihistamine drug which has been used clinically in Russia since 1983.

<span class="mw-page-title-main">Feprosidnine</span> Chemical compound

Feprosidnine (Sydnophen) is a stimulant drug which was developed in the USSR in the 1970s. It is structurally related to another Russian drug mesocarb but unlike mesocarb, was withdrawn earlier from production. In comparison with mesocarb it has own antidepressant activity, which makes it useful in treating depressions. Indications of feprosidnine included apathic, asthenic depressions, fatigue, apathic syndrome, narcolepsy and other similar conditions. Therapeutic range of doses: 10-50mg a day. Sydnophen has multiple mechanisms of action, the relative importance of which has not been clearly established. Effects on the body include reversible monoamine oxidase inhibition, cholinergic, adrenergic, opioid and nitric oxide donating actions, all of which may contribute to its pharmacological effects to some extent.

<span class="mw-page-title-main">Bromantane</span> Adaptogen

Bromantane, sold under the brand name Ladasten, is an atypical psychostimulant and anxiolytic drug of the adamantane family related to amantadine and memantine which is used in Russia in the treatment of neurasthenia. Although the effects of the bromantane have been determined to be dependent on the dopaminergic and possibly serotonergic neurotransmitter systems, its exact mechanism of action is unknown, and it is distinct in its properties relative to typical psychostimulants such as amphetamine. Because of its unique aspects, bromantane has sometimes been described instead as an adaptogen and actoprotector.

<i>N</i>-Phenylacetyl-<small>L</small>-prolylglycine ethyl ester Prodrug

N-Phenylacetyl-l-prolylglycine ethyl ester is promoted as a nootropic and is a prodrug of cyclic glycine-proline. Other names include the brand name Noopept, developmental code GVS-111; proposed INN omberacetam.

<span class="mw-page-title-main">Fabomotizole</span> Chemical compound

Fabomotizole is an anxiolytic drug launched in Russia in the early 2000s. It produces anxiolytic and neuroprotective effects without any sedative or muscle relaxant actions. Its mechanism of action remains poorly defined however, with GABAergic, NGF- and BDNF-release-promoting, MT1 receptor agonism, MT3 receptor antagonism, and sigma agonism suggested as potential mechanisms. Fabomotizole was shown to inhibit MAO-A reversibly and there might be also some involvement with serotonin receptors. Clinical trials have shown fabomotizole to be well tolerated and reasonably effective for the treatment of anxiety.

<span class="mw-page-title-main">Selank</span> Chemical compound

Selank is a nootropic, anxiolytic peptide based drug developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Selank is a heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). It is a synthetic analogue of human tuftsin.

<span class="mw-page-title-main">Emoxypine</span> Chemical compound

Emoxypine (2-ethyl-6-methyl-3-hydroxypyridine), also known as Mexidol or Mexifin when used as the succinate salt, is an antioxidant actoprotector manufactured by Pharmasoft Pharmaceuticals. Its chemical structure resembles that of pyridoxine (a type of vitamin B6).

<span class="mw-page-title-main">Semax</span> Chemical compound

Semax is a drug which is used mostly in Russia for a broad range of conditions but predominantly for its purported nootropic, neuroprotective, and neurorestorative properties. Semax has not been evaluated, approved for use, or marketed in most other countries. It is prescribed in eastern Europe and Russia for brain trauma.

<span class="mw-page-title-main">Adapromine</span> Chemical compound

Adapromine is an antiviral drug of the adamantane group related to amantadine (1-aminoadamantane), rimantadine, and memantine (1-amino-3,5-dimethyladamantane) that is marketed in Russia for the treatment and prevention of influenza. It is an alkyl analogue of rimantadine and is similar to rimantadine in its antiviral activity but possesses a broader spectrum of action, being effective against influenza viruses of both type A and B. Strains of type A influenza virus with resistance to adapromine and rimantadine and the related drug deitiforine were encountered in Mongolia and the Soviet Union in the 1980s.

Arabinopyranosyl-<i>N</i>-methyl-<i>N</i>-nitrosourea Chemical compound

Arabinopyranosyl-N-methyl-N-nitrosourea, also known as Aranose (Араноза) is a cytostatic anticancer chemotherapeutic drug of an alkylating type. Chemically it is a nitrosourea derivative. It was developed in the Soviet Union in the 1970s. It was claimed by its developers that its advantages over other nitrosoureas are a relatively low hematological toxicity and a wider therapeutic index, which allows for its outpatient administration.

<span class="mw-page-title-main">Tolibut</span> Chemical compound

Tolibut, also known as 3-(p-tolyl)-4-aminobutyric acid (or β-(4-methylphenyl)-GABA), is drug that was developed in Russia. It is an analogue of γ-aminobutyric acid (GABA) (that is, a GABA analogue) and is the 4-methyl analogue of phenibut, and is also an analogue of baclofen where the 4-chloro substitution has been replaced with a 4-methyl substitution. Tolibut has been described as possessing analgesic, tranquilizing, and neuroprotective properties. It is not fully clear as to whether the drug was ever approved or used medically in Russia.

<span class="mw-page-title-main">Leonid Lazebnik</span>

Leonid Borisovich Lazebnik is a Russian physician, Doctor of Medical Sciences, Professor at the Moscow State University of Medicine and Dentistry, President of the Gastroenterology Scientific Society of Russia. Laureate of the 1999 Moscow Government Prize and 2000 Myasnikov Russian Academy of Medical Sciences Prize.

References

  1. Flekhter, Oxana B. (2000). "Nooglutil, Russian Academy of Medical Science". Current Opinion in Central & Peripheral Nervous System Investigational Drugs. 2 (4): 491–497.
  2. V. V. Yasnetsov; V. A. Pravdivtsev; V. M. Popov; T. A. Voronina; N. M. Kiseleva; S. B. Kozlov (May 1995). "Antimotion Effect of Nooglutyl and Its Neuronal Mechanism". Bulletin of Experimental Biology and Medicine. 119 (5): 515–516. doi:10.1007/BF02543440. PMID   7579248. S2CID   6344628.
  3. Voronina, TA; Borlikova, GG; Garibova, TL; Proskuryakova, TV; Petrichenko, OB; Burd, SG; Avakyan, GN (2002). "Effect of nooglutil on benzodiazepine withdrawal syndrome and binding of 3H-spiperone with D2 receptors in rat striatum". Bulletin of Experimental Biology and Medicine. 134 (5): 448–50. doi:10.1023/a:1022634112815. PMID   12802448. S2CID   142803.
  4. Garibova, TL; Galaeva, IP; Voronina, TA; Kraĭneva, VA; Kapitsa, IG; Kirichenko, SV; Makarenko, AN; Mirzoian, GR; Kuznetsova, EA (2003). "Effect of nooglutil on rats with intracerebral posttraumatic hematoma (hemorrhagic stroke)". Eksperimental'naia i Klinicheskaia Farmakologiia. 66 (3): 13–6. PMID   12924225.
  5. Povarova, OV; Garibova, TL; Kalenikova, EI; Galaeva, IP; Kraĭneva, VA; Medvedev, OS; Voronina, TA (2004). "Effect of phenyl-tert-butylnitrone, mexidol and nooglutil on the ischemic lesion zone and memory in rats following middle cerebral artery occlusion". Eksperimental'naia i Klinicheskaia Farmakologiia. 67 (1): 3–6. PMID   15079898.